论文部分内容阅读
目的探讨阿托伐他汀治疗进展性脑梗死的临床效果,分析其对延缓脑梗死进展时间和降低神经功能缺损程度的作用。方法回顾性分析2008年6月—2010年6月采用阿托伐他汀治疗的128例进展性脑梗死患者的临床资料,并以同期采用依达拉奉注射液治疗的128例患者为对照组,比较两组治疗效果。结果两组患者入院后到神经功能缺损进展停止时均有明显增高,前后差异具有统计学意义,而到治疗结束时,两组患者NIHSS评分明显降低,观察组治疗结束时NIHSS评分分值为(3.47±1.07),对照组为(3.80±1.03),观察组治疗效果略高于对照组,但是组间差异无统计学意义(P>0.05)。观察组患者从发病到症状达峰值时间为(17.2±3.4)d,对照组患者从发病到症状达峰值时间为(14.7±2.1)d,观察组明显低于对照组,组间比较差异具有统计学意义(P<0.05)。结论阿托伐他汀治疗进展性脑梗死可明显缩短患者从发病到症状高峰时间,降低神经功能缺损程度。
Objective To investigate the clinical effect of atorvastatin on patients with progressive cerebral infarction and to analyze its effect on delaying the progress of cerebral infarction and reducing the degree of neurological deficits. Methods The clinical data of 128 patients with progressive cerebral infarction treated with atorvastatin from June 2008 to June 2010 were retrospectively analyzed. 128 patients treated with edaravone injection during the same period as control group, Compare the treatment effect of two groups. Results After admission, the neurological deficits in both groups were significantly higher than those in the control group, and the difference was statistically significant before and after treatment. At the end of treatment, NIHSS scores decreased significantly in both groups. NIHSS score at the end of treatment was ( 3.47 ± 1.07), and the control group was (3.80 ± 1.03). The treatment effect in the observation group was slightly higher than that in the control group, but there was no significant difference between the two groups (P> 0.05). In the observation group, the peak time from onset to symptom was (17.2 ± 3.4) days, and the peak time from onset to symptom in the control group was (14.7 ± 2.1) days. The observation group was significantly lower than the control group. The difference between the two groups was statistically significant Significance (P <0.05). Conclusion Atorvastatin treatment of patients with progressive cerebral infarction can significantly shorten the time from onset of symptoms to symptoms and reduce the degree of neurological deficits.